SCHEMBL15328004

SCHEMBL15328004

COc1cc(OC)c2cnc(-c3ccc(Nc4cccnc4)cc3)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 6/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
PDGFRB P09619 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
PDGFRA P16234 1/20 0.45
MAPK1 P28482 1/20 0.45
CASP1 P29466 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ABCB1 P08183 3/20 0.43
CYP19A1 P11511 1/20 0.43
LATS1 O95835 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328263 0.89 PDGFRB (0.54) ABCG2MEN1KMT2AMAPTALDH1A1
SCHEMBL15328208 0.85 MAPT (0.47) ABCG2MEN1KMT2AMAPTALDH1A1
SCHEMBL348341 0.80 PDGFRB (0.67) ABCG2MEN1KMT2AMAPTALDH1A1
SCHEMBL1304390 0.80 PDGFRB (0.51) ABCG2MEN1KMT2AMAPTALDH1A1
SCHEMBL15533402 0.77 ALDH1A1 (0.48) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL346309 0.77 PDGFRB (0.50) ABCG2MEN1KMT2AMAPTALDH1A1
SCHEMBL348350 0.75 CYP1A2 (0.47) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL23068690 0.74 CYP1A2 (0.54) ABCG2MEN1KMT2AMAPTALDH1A1
SCHEMBL377957 0.73 BRD4 (0.53)
SCHEMBL15329252 0.72 FYN (0.49) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 ABCG2 4725/4885MEN1 4236/4885KMT2A 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.